FDA Puts Cell Therapeutics, Inc. Blood Cancer Drug on Hold After Death
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Cell Therapeutics Inc said the U.S. Food and Drug Administration has placed a partial clinical hold on the company's experimental blood cancer drug after the death of a patient. The patient, being treated with the drug tosedostat in combination with a chemotherapy drug, died of myocarditis, or infection of the heart muscle, the company said in a regulatory filing on Monday.
Help employers find you! Check out all the jobs and post your resume.
Cell Therapeutics Inc said the U.S. Food and Drug Administration has placed a partial clinical hold on the company's experimental blood cancer drug after the death of a patient. The patient, being treated with the drug tosedostat in combination with a chemotherapy drug, died of myocarditis, or infection of the heart muscle, the company said in a regulatory filing on Monday.
Help employers find you! Check out all the jobs and post your resume.